ఇండెక్స్ చేయబడింది
  • RefSeek
  • హమ్దార్డ్ విశ్వవిద్యాలయం
  • EBSCO AZ
  • OCLC- వరల్డ్ క్యాట్
  • SWB ఆన్‌లైన్ కేటలాగ్
  • పబ్లోన్స్
  • ఇంటర్నేషనల్ కమిటీ ఆఫ్ మెడికల్ జర్నల్స్ ఎడిటర్స్ (ICMJE)
  • జెనీవా ఫౌండేషన్ ఫర్ మెడికల్ ఎడ్యుకేషన్ అండ్ రీసెర్చ్
ఈ పేజీని భాగస్వామ్యం చేయండి

నైరూప్య

Ketamine’s Journey from Sedation to Suicide Prevention: A Viewpoint

Saeed Ahmed, Mudasar Hassan, Hema Venigalla, Hema Madhuri Mekala and Mustafa Qureshi

Suicide is the tenth leading cause of death in the United States. According to research in 2016, the suicide rate has increased substantially both in the United States and worldwide. Most people who commit suicide are found to suffer from psychiatric illnesses like depression, schizophrenia, anxiety, bipolar disorder, alcoholism, and posttraumatic stress disorder (PTSD). In the past several studies are conducted to examine which drugs decrease suicidal ideation in mentally ill patients. Selective serotonin reuptake inhibitors (SSRIs) like Prozac (fluoxetine) are believed to decrease suicidal intentions in patients with depressive disorders. Similarly, lithium and clozapine are effective in reducing suicidality in patients with bipolar depression and schizophrenia, respectively. Although these drugs have a demonstrated efficacy to reduce suicidality long-term, there is limited evidence that these drugs have the same effect during the acute phase of illness. Most psychotropic medications take a few weeks to work; unfortunately, some patients require sufficiently more time to stabilize their symptoms. Because time is a crucial factor when dealing with suicidal patients, we express our viewpoint regarding the use of ketamine, which may, within hours or days help patients with suicidal ideation.

నిరాకరణ: ఈ సారాంశం ఆర్టిఫిషియల్ ఇంటెలిజెన్స్ టూల్